Lyfnua

RSS

gefapixant

Authorised
This medicine is authorised for use in the European Union.

Overview

Lyfnua is a medicine used to treat adults with chronic (long-term) cough which is unexplained or for which other treatments have not worked.

The medicine contains the active substance gefapixant.

This EPAR was last updated on 10/10/2023

Authorisation details

Product details
Name
Lyfnua
Agency product number
EMEA/H/C/005476
Active substance
Gefapixant
International non-proprietary name (INN) or common name
gefapixant
Therapeutic area (MeSH)
Cough
Anatomical therapeutic chemical (ATC) code
R05DB29
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Merck Sharp & Dohme B.V.
Date of issue of marketing authorisation valid throughout the European Union
15/09/2023
Contact address

Waarderweg 39
2031 BN Haarlem
The Netherlands

Product information

Lyfnua - EMEA/H/C/005476 -

Other EU languages available icon This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.

 

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Cough and cold preparations

Therapeutic indication

Lyfnua is indicated in adults for the treatment of refractory or unexplained chronic cough.

Assessment history

How useful was this page?

Add your rating
Average
1 rating